BioAge Labs has completed its upsized initial public offering (IPO), raising $198 million after increasing the number of shares on offer by 40%.The expansion of the listing reflects the massive investor appetite for companies with assets in the clinic for obesity and takes the on-paper value of the Richmond, California-based company above $600 million.

。上市规模的扩大反映了投资者对拥有肥胖症诊所资产的公司的巨大兴趣，并使这家总部位于加利福尼亚州里士满的公司的账面价值超过6亿美元。

BioAge sold 11 million shares at a price of $18 apiece, well above its earlier estimate of 7.5 million.The IPO, which should see BioAge start trading on the Nasdaq today under the BIOA symbol, follows a $170 million Series D financing which completed in February and was earmarked for its phase 2 trials programme.The company is focusing on the development of oral apelin receptor (APJ) agonist azelaprag, currently in a phase 2 trial in combination with Eli Lilly's FDA-approved obesity therapy Zepbound (tirzepatide), with results due in the third quarter of 2025.The biotech believes that azelaprag can amplify the weight loss achieved with tirzepatide and other obesity drugs – including Novo Nordisk's Wegovy (semaglutide) – and also improve the body composition of treated patients by preserving muscle function.BioAge was founded in 2015 with a focus on diseases related to ageing, and was initially developing azelaprag for muscle atrophy in the over-65s before pivoting to an obesity programme a year ago.

BioAge以每股18美元的价格出售了1100万股股票，远高于此前750万股的估计。此次IPO将于今日在Nasdaq以BIOA标志开始交易，此前D轮融资1.7亿美元，已于2月完成，并指定用于其第二阶段试验计划。该公司专注于开发口服apelin受体（APJ）激动剂阿泽拉普拉格，目前正在与礼来公司（Eli Lilly）的FDA批准的肥胖治疗药物Zepbound（tirzepatide）联合进行2期临床试验，结果将于2025年第三季度公布。该生物技术公司认为，阿泽拉普拉格可以扩大使用tirzepatide和其他肥胖药物（包括诺和诺德（Novo Nordisk）的Wegovy（semaglutide））实现的体重减轻，还可以通过保留肌肉功能来改善治疗患者的身体成分。BioAge成立于2015年，专注于与衰老有关的疾病，最初开发用于65岁以上肌肉萎缩的阿扎拉普拉格，一年前转向肥胖计划。

In a phase 1b study, the drug was shown to achieve a significant increase in muscle mass and quality compared to placebo over 10 days of bed rest.Azelaprag was formerly owned by Amgen, which was looking at it as a potential therapy for heart failure but discontinued the programme after disappointing trial results.

在一项1b期研究中，与安慰剂相比，该药物在卧床休息10天后肌肉质量和质量显着增加。Azelaprag以前归安进所有，安进将其视为心力衰竭的潜在治疗方法，但在试验结果令人失望后停止了该计划。

BioAge licensed exclusive worldwide rights to it in 2021.BioAge says its long-term plan is to develop an all-oral .

BioAge于2021年获得全球独家使用权。BioAge表示，其长期计划是开发全口服。